Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kowa Receives Approval for Glaucoma Treatment Glanatec
October 1, 2014
- AZ Was Concerned with Pfizer’s Possible Takeover Deal Withdrawal Due to US Anti-Inversion Move: CEO
September 30, 2014
- e-Detailing Powerhouse M3 to Establish New Firm Dedicated to CSO Biz
September 30, 2014
- Lixiana OK’d for Stroke Prevention in Japan: Daiichi Sankyo
September 30, 2014
- Daiichi Sankyo to Buy US Biotech Ambit, Beef Up Oncology Portfolio
September 30, 2014
- Kyowa Kirin’s Neutropenia Treatment G-Lasta Approved
September 30, 2014
- JCR Files NDA for Japan’s 1st Cell-Based Drug JR-301
September 30, 2014
- Sumitomo Dainippon, SanBio to Jointly Develop Cell Therapy Agent for Chronic Stroke in North America
September 30, 2014
- Ixekizumab Improves Skin Lesions in Japanese Psoriasis Patients: Eli Lilly Japan
September 30, 2014
- Avigan Administered to Ebola-Infected French Woman: Fujifilm
September 29, 2014
- Sanofi’s 2013 Payments to Healthcare Professionals Down 11%
September 29, 2014
- Novartis Files Panobinostat for Multiple Myeloma in Japan
September 29, 2014
- Sanofi Opens Asia Pacific Development Hub in Shanghai
September 29, 2014
- Ribomic Goes Public, Aims to Swing to Black on Aptamers
September 26, 2014
- NBI Paid 14.6 Billion Yen to Healthcare Professionals in 2013
September 26, 2014
- Takeda to Invest 2.5 Billion Yen in US Firm for New Drug Development
September 26, 2014
- OncoTherapy Science Appoints Masaharu Mori, Formerly of Shionogi and Novartis Pharma, as New President
September 26, 2014
- Eisai Sets Up Director Position for Pariet
September 26, 2014
- US FDA Accepts NDA for Abilify Successor Brexpiprazole: Otsuka, Lundbeck
September 26, 2014
- AZ Managed to Speed Up Pilot R&D Projects under New Structure: President
September 25, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…